Johnson & Johnson Q3 Results - Q3 Top Pharma Company Earnings Reports

View Johnson & Johnson's Q3 Earnings Report

FiercePharma says: Market reaction to Johnson & Johnson's earnings announcement reflects an overall worry about cost-cutting versus sales growth. Yes, J&J beat expectations, posting earnings of $1.20 per share, about 7 cents higher than analysts had estimated. But third-quarters sales came in at $15.1 billion, which fell short of those same estimates. At press time, the stock had fallen 2.62 percent, or $1.64, to $60.89. Read more of our coverage here...

Highlights:

  • Sales of $15.1 Billion Decreased 5.3% Versus 2008 Third Quarter
  • EPS of $1.20 increased 2.6% Versus 2008 Third Quarter

Check out J&J's current earnings estimates from CNN Money

J&J's Website: http://www.jnj.com/connect/

Johnson & Johnson Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

Ibrance
Pharma

SABCS: Pfizer backs Ibrance with real-world breast cancer data

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

by Kyle Blankenship
Sanofi mobile robots
Manufacturing

Sanofi CEO turns to 'cobots' and AI to zap manufacturing costs 

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

by Eric Palmer
White House
Pharma

Trump admin pulls biologic drug protections from trade deal

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

by Eric Sagonowsky